Chikungunya - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 90 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chikungunya - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chikungunya - Pipeline Review, H1 2016', provides an overview of the Chikungunya pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chikungunya, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chikungunya and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chikungunya
- The report reviews pipeline therapeutics for Chikungunya by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chikungunya therapeutics and enlists all their major and minor projects
- The report assesses Chikungunya therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chikungunya

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chikungunya
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chikungunya pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Content 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Chikungunya Overview 10
Therapeutics Development 11
Pipeline Products for Chikungunya - Overview 11
Pipeline Products for Chikungunya - Comparative Analysis 12
Chikungunya - Therapeutics under Development by Companies 13
Chikungunya - Therapeutics under Investigation by Universities/Institutes 15
Chikungunya - Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Chikungunya - Products under Development by Companies 18
Chikungunya - Products under Investigation by Universities/Institutes 19
Chikungunya - Companies Involved in Therapeutics Development 20
Abivax S.A. 20
Arbovax, Inc. 21
Arno Therapeutics, Inc. 22
Bharat Biotech International Limited 23
Etubics Corporation 24
Indian Immunologicals Limited 25
Inovio Pharmaceuticals, Inc. 26
Integral Molecular, Inc. 27
Integrated BioTherapeutics, Inc. 28
Merck & Co., Inc. 29
Nanotherapeutics, Inc. 30
PaxVax, Inc. 31
Profectus BioSciences, Inc. 32
Takeda Pharmaceutical Company Limited 33
Themis Bioscience GmbH 34
Valneva SE 35
Chikungunya - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
ABX-309 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Antibody for Chikungunya - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
AR-12 - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
chikungunya (viral like particles) vaccine - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
chikungunya vaccine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
chikungunya vaccine - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
chikungunya vaccine - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
chikungunya vaccine - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
chikungunya vaccine - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
chikungunya vaccine - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
chikungunya vaccine - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
chikungunya vaccine - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
chikungunya vaccine - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
chikungunya vaccine - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
chikungunya vaccine - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
chikungunya vaccine - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
chikungunya vaccine - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
chikungunya vaccine - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
chikungunya vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
DEF-201 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IMCKV-063 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Monoclonal Antibodies for Chikungunya - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Monoclonal Antibodies to Inhibit Viral E1/E2 Proteins for Chikungunya - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Monoclonal Antibody for Chikungunya - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
MV-CHIK - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Small Molecule to Inhibit NS2 and NS3 for Chikungunya - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Small Molecules to Inhibit Viral RNA for Chikungunya Virus Infections - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Chikungunya - Recent Pipeline Updates 76
Chikungunya - Dormant Projects 80
Chikungunya - Product Development Milestones 81
Featured News & Press Releases 81
Mar 22, 2016: Inovio's DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study 81
Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs 82
Mar 02, 2015: Themis Bioscience's Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases 84
Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus 84
Nov 20, 2014: Themis Bioscience's Vaccine Against Chikunguya Successful In Phase 1 85
Jun 12, 2014: Threat of Emerging Virus can be Stopped: Interim results of First Clinical Trial of Themis Bioscience's Vaccine Candidate Against Chikungunya Fever Prove Successful 86
Mar 27, 2013: Themis Bioscience Plans To Initiate Phase I Study Of Chikungunya Fever Vaccine Candidate 87
Aug 15, 2011: Inviragen And University of Texas Medical Branch Receive Funding For Development Of Chikungunya Virus Vaccine 87
Nov 04, 2010: Novel Recombinant Chikungunya Virus Vaccine Shown To Be Safe And Effective In Multiple Animal Models 88
Nov 02, 2010: Inviragen Receives Two Therapeutic Discovery Project Grants For Vaccine Development 88
Appendix 89
Methodology 89
Coverage 89
Secondary Research 89
Primary Research 89
Expert Panel Validation 89
Contact Us 89
Disclaimer 90

List of Tables

Number of Products under Development for Chikungunya, H1 2016 11
Number of Products under Development for Chikungunya - Comparative Analysis, H1 2016 12
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 15
Comparative Analysis by Clinical Stage Development, H1 2016 16
Comparative Analysis by Early Stage Development, H1 2016 17
Products under Development by Companies, H1 2016 18
Products under Investigation by Universities/Institutes, H1 2016 19
Chikungunya - Pipeline by Abivax S.A., H1 2016 20
Chikungunya - Pipeline by Arbovax, Inc., H1 2016 21
Chikungunya - Pipeline by Arno Therapeutics, Inc., H1 2016 22
Chikungunya - Pipeline by Bharat Biotech International Limited, H1 2016 23
Chikungunya - Pipeline by Etubics Corporation, H1 2016 24
Chikungunya - Pipeline by Indian Immunologicals Limited, H1 2016 25
Chikungunya - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 26
Chikungunya - Pipeline by Integral Molecular, Inc., H1 2016 27
Chikungunya - Pipeline by Integrated BioTherapeutics, Inc., H1 2016 28
Chikungunya - Pipeline by Merck & Co., Inc., H1 2016 29
Chikungunya - Pipeline by Nanotherapeutics, Inc., H1 2016 30
Chikungunya - Pipeline by PaxVax, Inc., H1 2016 31
Chikungunya - Pipeline by Profectus BioSciences, Inc., H1 2016 32
Chikungunya - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 33
Chikungunya - Pipeline by Themis Bioscience GmbH, H1 2016 34
Chikungunya - Pipeline by Valneva SE, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Stage and Target, H1 2016 38
Number of Products by Stage and Mechanism of Action, H1 2016 40
Number of Products by Stage and Route of Administration, H1 2016 42
Number of Products by Stage and Molecule Type, H1 2016 44
Chikungunya Therapeutics - Recent Pipeline Updates, H1 2016 76
Chikungunya - Dormant Projects, H1 2016 80